Moreover, whether MASLD, especially its more advanced fibrotic stages, modifies the association between Lp-PLA2 and atherosclerosis in the high-risk T2DM population is unknown. This evidence concerns the gene PLA2G7 and metabolic dysfunction-associated steatotic liver disease.